|
Jun 2
|
Are Options Traders Betting on a Big Move in Merck Stock?
|
|
Jun 2
|
Bristol Myers allies with BioNTech on bispecific cancer drug
|
|
May 31
|
KEYTRUDA® (pembrolizumab) Plus Trodelvy® (sacituzumab govitecan-hziy) Reduced Risk of Disease Progression or Death by 35% Versus KEYTRUDA Plus Chemotherapy in First-Line PD-L1+ Metastatic Triple-Negative Breast Cancer (TNBC)
|
|
May 30
|
ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial
|
|
May 30
|
Summit Therapeutics, A Top 1% Biotech, Plummets On A High-Profile Failure
|
|
May 30
|
Merck Announces MK-1084, an Investigational KRAS G12C Inhibitor, Shows Antitumor Activity in Phase 1 Trial of Patients With Advanced Colorectal Cancer and Non-Small Cell Lung Cancer Whose Tumors Harbor KRAS G12C Mutations
|
|
May 30
|
Merck’s Investigational Zilovertamab Vedotin at 1.75 mg/kg Dose Plus Standard of Care Showed Promising Antitumor Activity, Including Complete Response Rate, in Patients With Relapsed/Refractory DLBCL in Phase 2 Portion of waveLINE-003 Trial
|
|
May 30
|
2 Cash-Producing Stocks for Long-Term Investors and 1 to Steer Clear Of
|
|
May 29
|
Merck KGaA (MKGAF) Files for Global Approval of Pimicotinib After Positive Phase III TGCT Results
|
|
May 29
|
Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
|
|
May 29
|
Moderna suffers a $750 million loss from NIH funding cut
|
|
May 29
|
Patritumab Deruxtecan Biologics License Application for Patients with Previously Treated Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer Voluntarily Withdrawn
|
|
May 28
|
Merck (NYSE:MRK) Declares US$0.81 Dividend for Q3 2025 Payout
|
|
May 27
|
Merck Announces Third-Quarter 2025 Dividend
|
|
May 23
|
Merus Skyrockets On 'Unprecedented' Cancer Results, Slamming Bicara Therapeutics
|
|
May 23
|
3 Dow Jones Stocks on Our Watchlist
|
|
May 22
|
Merck to Participate in the Bernstein 41st Annual Strategic Decisions Conference
|
|
May 16
|
Merck to Present New Clinical and Outcomes Research Data at The American Thoracic Society’s (ATS) 2025 International Conference Demonstrating Commitment to Advancing Research in Pulmonary Arterial Hypertension
|
|
May 15
|
FDA awards cancer drug approvals to AbbVie and MSD
|
|
May 15
|
FDA approves Merck’s belzutifan for pheochromocytoma or paraganglioma
|